Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
ConvaTec ( (GB:CTEC) ) just unveiled an update.
Convatec Group Plc announced the grant of share options under its 2017 Save as You Earn scheme to interim executives Jonny Mason and Fiona Ryder. These options, covering a total of 18,686 ordinary shares, are exercisable from September 2028, reflecting the company’s commitment to aligning managerial interests with long-term shareholder value.
The most recent analyst rating on (GB:CTEC) stock is a Hold with a £263.00 price target. To see the full list of analyst forecasts on ConvaTec stock, see the GB:CTEC Stock Forecast page.
Spark’s Take on GB:CTEC Stock
According to Spark, TipRanks’ AI Analyst, GB:CTEC is a Neutral.
ConvaTec’s overall stock score is driven primarily by its strong financial performance, characterized by robust revenue growth and effective cash flow management. Technical analysis indicates a stable market sentiment, while valuation metrics suggest caution due to a high P/E ratio. The absence of earnings call insights and notable corporate events leaves the financial performance as the most significant factor in the evaluation.
To see Spark’s full report on GB:CTEC stock, click here.
More about ConvaTec
Convatec is a global medical products and technologies company specializing in solutions for managing chronic conditions. The company holds leading positions in Advanced Wound Care, Ostomy Care, Continence Care, and Infusion Care, offering products and services in around 90 countries. Convatec’s solutions aim to improve patient outcomes and reduce care costs, with revenues exceeding $2 billion in 2024. The company is listed on the FTSE 100 Index.
Average Trading Volume: 7,722,048
Technical Sentiment Signal: Hold
Current Market Cap: £4.79B
See more insights into CTEC stock on TipRanks’ Stock Analysis page.